secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000950170-25-026103
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q4/FY2024 net loss $67.9M/$255.9M; SUMMIT results due July 2025
--------------------------------------------------------------------------------

- Net loss Q4 $67.9M, FY $255.9M (vs $54.4M and $192.4M); R&D spend $62M/$232.7M.
- Cash, equivalents and marketable securities $287.1M at 12/31/24 plus $25M from ATM; runway into late 2026.
- Top-line SUMMIT (NonAdvSM) results expected July 2025; APEX (AdvSM) enrollment complete, data 2H 2025.
- NDA submission for bezuclastinib planned by end-2025; PEAK (GIST) top-line by end-2025.
- Preclinical IND for ErbB2 inhibitor CGT4255 and PI3Kα inhibitor CGT6297 planned in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017025026103/0000950170-25-026103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017025026103/cogt-20250225.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-026103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer